Raia Drogasil S.A. (OTCMKTS:RADLY) Sees Large Drop in Short Interest

Raia Drogasil S.A. (OTCMKTS:RADLYGet Free Report) saw a significant decline in short interest during the month of May. As of May 15th, there was short interest totaling 478 shares, a decline of 53.7% from the April 30th total of 1,032 shares. Based on an average trading volume of 11,859 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the shares of the stock are sold short.

Analysts Set New Price Targets

Separately, Zacks Research raised Raia Drogasil to a “hold” rating in a research report on Thursday, April 9th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company has an average rating of “Hold”.

Read Our Latest Research Report on Raia Drogasil

Raia Drogasil Stock Performance

OTCMKTS RADLY traded down $0.23 during midday trading on Monday, hitting $3.61. The company had a trading volume of 35,748 shares, compared to its average volume of 20,753. The firm has a fifty day simple moving average of $4.34 and a two-hundred day simple moving average of $4.52. Raia Drogasil has a fifty-two week low of $2.17 and a fifty-two week high of $5.34.

About Raia Drogasil

(Get Free Report)

Raia Drogasil SA is a leading Brazilian retail pharmacy operator, offering a comprehensive range of prescription and over-the-counter medications, health and wellness products, personal care and beauty items, as well as a selection of convenience goods. The company’s network of stores operates under the Raia and Drogasil banners, serving diverse consumer needs across major urban centers. Complementary services include in-store prescription dispensing, compounding pharmacies and health screening programs such as blood pressure and glucose monitoring.

The company was formed in 2011 through the merger of two established Brazilian pharmacy chains, Drogasil and Droga Raia, each with origins dating back several decades.

Recommended Stories

Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.